| scholarly article | Q13442814 |
| P2093 | author name string | Gary Remington | |
| George Foussias | |||
| Robert B Zipursky | |||
| Hiroyoshi Takeuchi | |||
| Gagan Fervaha | |||
| Ofer Agid | |||
| Cynthia Siu | |||
| P2860 | cites work | Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia | Q39636947 |
| The PANSS should be rescaled | Q40849281 | ||
| Psychobiologic correlates of treatment response in schizophrenia | Q41160155 | ||
| Comparison of treatment response in second-episode versus first-episode schizophrenia | Q45043977 | ||
| What does the PANSS mean? | Q46570213 | ||
| Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. | Q50737435 | ||
| Early treatment resistance in a Latin-American cohort of patients with schizophrenia. | Q51412568 | ||
| Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. | Q51959302 | ||
| Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. | Q51996001 | ||
| What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? | Q55023835 | ||
| Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies | Q88989907 | ||
| Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis | Q28266069 | ||
| Should the PANSS be rescaled? | Q33890074 | ||
| Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies | Q34545159 | ||
| Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies | Q35042829 | ||
| Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review | Q37248065 | ||
| Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials | Q37451403 | ||
| Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. | Q37576827 | ||
| Dose equivalents for second-generation antipsychotics: the minimum effective dose method | Q37598284 | ||
| The evidence for illness progression after relapse in schizophrenia | Q38113634 | ||
| Does active psychosis cause neurobiological pathology? A critical review of the neurotoxicity hypothesis | Q38143298 | ||
| A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders | Q38281460 | ||
| Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone | Q38375153 | ||
| How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. | Q38697770 | ||
| The Cost of Relapse in Schizophrenia. | Q38769604 | ||
| The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia | Q38803633 | ||
| Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. | Q38948958 | ||
| Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology | Q39029626 | ||
| Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. | Q39328454 | ||
| P433 | issue | 6 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 1036-1042 | |
| P577 | publication date | 2018-11-22 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia | |
| P478 | volume | 44 |
| Q90264425 | Caregiver Burdens Associated With Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes, and Perceptions |
| Q90264428 | Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View |
| Q92515332 | Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support |
| Q92460997 | Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists |
| Q64999981 | Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. |
| Q92695687 | Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study |
| Q98627662 | Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis |
| Q92480512 | The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research |
| Q96773916 | The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia |
Search more.